As a coda to today's post, attention is drawn to the attached article here that appeared on Bloomberg
And so the challenge to Pharma becomes increasingly immediate and increasingly substantial.
"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.
Post a Comment